China Resources Double-Crane Pharmaceutical Co., Ltd.SSE: 600062

(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Vortioxetine Hydrobromide by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.

· Issued by China Resources Double-Crane Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600062 · · 3 pages · Chinese

Summary by 6ix AI

China Resources Double-Crane Pharmaceutical Co., Ltd. announced that its subsidiary has received approval for the marketing application of Vortioxetine Hydrobromide, a chemical API.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/600062china-resources-double-crane-pharmaceutical-co-ltdannouncement-on-obtaining-the-approval-notice-for-marketing-application-of-the-chemical-api-vortioxetine-hydrobromide-by-the-controlled-subsidiary-china-resources-double-crane-xiangzhong-pharmaceutical-hunan-co-ltd

Release

Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Vortioxetine Hydrobromide by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from China Resources Double-Crane Pharmaceutical

Later from China Resources Double-Crane Pharmaceutical

All China Resources Double-Crane Pharmaceutical news releases